MedTrace Logo

Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRILLATION

NCT06134739 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-01-11

No results posted yet for this study

Summary

The EMBOL-AF is a multicenter, international, observational study designed as a retrospective registry that will investigate the characteristics of systemic arterial embolic events after treatment of atrial fibrillation by catheter ablation. Due to the retrospective nature of the study, the registry is specially focused on cerebral embolism (stroke and TIA) because these are not only the most frequent and clinically relevant but also the most susceptible to underreporting. However, all embolism associated to AFAbl will be included.

This study will gather all clinically relevant aspects and data of all cases of arterial embolism that have occurred over the last 5 years in the centers that will participate in the registry. Based on these reported cases, the incidence, management and outcomes of embolic events (particularly stroke and TIA) will be studied.

Conditions

Interventions

OTHER

No intervention.

Observational study, no intervention.

Sponsors & Collaborators

  • 3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.

    collaborator UNKNOWN

  • Department of Rhythmology, University Hospital Schleswig-Holstein, Lübeck, Germany.

    collaborator UNKNOWN

  • Hospital Universitario La Paz

    lead OTHER

Principal Investigators

  • José Luis Merino Llorens, MD PhD · La Paz University Hospital. Madrid. Spain.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2024-12-01
Completion
2024-12-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06134739 on ClinicalTrials.gov